Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Contact Us
AUA Advocacy Communications
10 G Street NE
Suite 600
Washington, D.C. 20002
1-866-RING-AUA (toll-free)
410-689-3810 (direct)
Email
CY 2027 Medicare Shared Savings Program and the Quality Payment Program Summary
On November 4, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule (MPFS) final rule for CY 2027 (CMS-1848-F). This rule makes changes to the Quality Payment Program (QPP). Fact sheets for the Medicare Shared Savings Program (MSSP) and the Quality Payment Program are available.
Note that the page numbers listed in this document refer to the display copy of the proposed rule.
Medicare Shared Savings Program (MSSP) – p. 986
Highlight: CMS finalized significant changes to the Medicare Shared Savings Program (MSSP) aimed at strengthening financial incentives for Accountable Care Organizations (ACOs), expanding participation, reducing administrative burden, and improving care affordability and quality, including increasing shared savings rates and allowing ACOs to reduce certain patient out-of-pocket costs.
In the final rule, CMS retained the central MSSP reforms, including changes to financial incentives, benchmarking, beneficiary assignment, quality reporting, and beneficiary cost-sharing. CMS did not substantially reverse its proposed MSSP policies in response to public comments. CMS estimates that the MSSP policy provisions in this final rule are projected to reduce Trust Fund expenditures by $5.5 billion in total for the 10-year period ending in 2036.
MSSP Beneficiary Assignment Methodology (p. 997): Beginning January 1, 2028, CMS will revise how beneficiaries are assigned to ACOs by finalizing proposals such as:
- Excluding primary care services billed outside an ACO's Taxpayer Identification Number (TIN) to prevent billing patterns that could unfairly increase ACO savings (p. 1016).
- Revising beneficiary eligibility to require at least one month of both Part A and Part B enrollment, without Medicare Advantage or other Medicare group health plan enrollment during that same month, within the 12-month assignment window (p. 1034).
- Expanding the definition of primary care services used for beneficiary assignment to include new HCPCS codes, including those for Screening, Brief Intervention, and Referral to Treatment (SBIRT) (G2011), Vaccine Adverse Effects Management (G0576), and Advance Care Planning (G0572, G0573), starting on January 1, 2027 (p. 1062).
Modifier B2 for MSSP ACOs: CMS finalized proposals to replace the G2211 visit complexity add-on code with two new modifiers beginning on January 1, 2027: B1, which increases payments for eligible evaluation and management visits by 16%, and B2, which provides a higher 32% increase for clinicians participating in MSSP ACOs or the LEAD Model.
MSSP Quality Performance and Reporting (p. 1,074):
- CMS finalized proposals to extend the availability of the Merit-based Incentive Payment System (MIPS) Clinical Quality Measures (CQMs) collection type beginning with January 1, 2027, to help ACOs avoid the administrative burden of switching reporting methods while transitioning to digital quality reporting. CMS will also extend related reporting incentives to help ACOs meet quality performance requirements, qualify for higher shared savings payments, and avoid the maximum financial penalties for losses for ACOs in the ENHANCED track.
- CMS also extends the scoring of Shared Savings Program ACOs reporting Medicare CQMs using flat benchmarks for Performance Year (PY) 2027 and subsequent PYs (p.1087). In addition, the Diabetes: Glycemic Status Assessment Greater Than 9% (Quality ID: 001), Preventive Care and Screening: Screening for Depression and Follow-up Plan (Quality ID: 134) and Controlling High Blood Pressure (Quality ID: 236), if reported via the Medicare CQMs collection type for PY 2026 (and subsequent PYs), will be scored using flat benchmarks.
- CMS finalized revising the quality reporting requirements for Shared Savings Program, given the concerns raised by ACOs about challenges meeting the requirements (p.1113). Beginning in PY 2026, ACOs may exclude certain participating practices from quality reporting due to unexpected closures, limitations in specialty electronic health records, or other CMS-approved circumstances, provided their reporting still covers at least 95% of assigned beneficiaries.
- CMS finalized to establish a new collection type—Medicare electronic CQMs (eCQMs)—which would only be available to Shared Savings Program ACOs reporting the APP Plus quality measure set for PY 2027 and subsequent PYs to reduce reporting challenges and support the transition to digital quality reporting (p.1142).
- CMS is revising the definition of a “Beneficiary Eligible for Medicare CQMs” to more closely align with an ACO’s assigned Medicare beneficiaries (p.1161).
- CMS finalized the revisions to the Shared Savings Program scoring policy for excluded CMS APM Performance Pathway (APP) plus measures and APP plus measures that lack a benchmark (p.1171). Beginning in 2027, CMS will apply the scoring method only when fewer than five quality measures can be used to calculate an ACO’s score, rather than when a required measure lacks a benchmark.
- Beginning in 2027, CMS is reducing the APP Plus quality measure for Shared Savings Program ACOs to eight measures as previously proposed, removing substance use disorder treatment initiation and engagement (Quality ID: 305) and adult immunization status (Quality ID: 493). (p. 1184).
Certified Electronic Health Record Technology (CEHRT) (p.1,189): CMS finalized proposals to simplify Shared Savings Program CEHRT use requirements to reduce participant burden. Beginning in 2027, CMS will allow ACOs to choose from three options: (1) electronically reporting at least one quality measure using CEHRT, (2) using FHIR-based technology to support quality reporting, or (3) attesting to electronic prescribing, health information exchange, or provider-to-patient information exchange. ACOs may exclude certain participating providers facing qualifying hardships or special circumstances but must maintain supporting documentation and publicly report which option they selected.
Shared Savings Program’s Financial Methodology (p.1,258): CMS finalized proposals aiming to strengthen financial incentives to participate and encourage additional savings in two-sided risk by:
- Increasing the shared savings rate under BASIC track Level E from 50% to 60% (p.1263)
- Reducing the maximum weight used to calculate the positive regional adjustment for ENHANCED track ACOs from 50% to 35% (p.1281)
- Increasing the prior savings adjustment’s scaling factor from 50% to 75% (p.1320)
- Risk adjusting the 5% cap on three upward adjustments (regional adjustment, prior savings adjustment, and population adjustment) to the historical benchmark (p.1340)
Given the timing of the CY 2027 MPFS final rule and the Shared Savings Program application cycle, CMS is allowing ACO applicants seeking a January 1, 2027, start date to revise their final participation track or level selection during November 12–17, 2026, following publication of the final rule.
CMS also finalized a growth adjustment to the historical benchmark to reward ACOs for recruiting ACO professionals who are inexperienced with value-based care arrangements and serving beneficiaries new to value-based care (p.1366) and reformed the Accountable Care Prospective Trend (ACPT) component of the benchmark update factor (p.1401).
Beneficiary Engagement (p.1,451): Beginning April 1, 2027, CMS will allow approved ACOs to reduce or eliminate Medicare Part B out-of-pocket costs for certain services, excluding prescription drugs and medical equipment, to make care more affordable for beneficiaries; applications will open in early 2027. CMS is also ending the prepaid shared savings payment option, with no new applications accepted after the January 1, 2027, start-date application cycle and payments to existing participants continuing through December 31, 2027 (p.1477).
Advance Investment Payments Changes (p.1,490): CMS finalized proposals to modify the calculation methodology for setting quarterly advance investment payments. Beginning in 2028, ACOs will receive $45 per quarter for each beneficiary who qualifies for Medicare Part D low-income assistance, is enrolled in both Medicare and Medicaid, or lives in a rural area, and $25 per quarter for other beneficiaries, with payments for the latter group capped at 10,000 beneficiaries.
Identifying ACOs Experienced with Performance-Based Risk Medicare ACO Initiatives (p.1,505): Beginning January 1, 2027, CMS will change how it determines whether an ACO has prior experience taking on financial risk, which affects whether it can enter lower-risk participation options or must join higher-risk tracks. Under the new policy, CMS will only count an ACO participant’s prior involvement in a risk-based Medicare ACO program if it had a written participation agreement, preventing organizations without such agreements from being classified as experienced solely because they were included in the program’s financial calculations.
Revising Beneficiary Notification Requirements (p.1,512): CMS finalized proposals to simplify beneficiary notification requirements by allowing ACOs to provide a standardized written notice at least once during their agreement period, rather than at a patient’s first primary care visit, beginning January 1, 2027. The notice must be provided by May 30, and ACOs will no longer be required to send follow-up communications, reducing administrative burden and potential confusion for patients.
Request for Information (RFI) for Specialty Care in the Shared Savings Program (p.1,524): In the proposed rule, CMS requested public input on potential approaches to more effectively integrate and meaningfully engage specialty care in the Shared Savings Program. CMS responded that the agency will be reviewing the comments it received and will consider them for future rulemaking, technical assistance, and policy development.
Updates to the Quality Payment Program – p. 1,552
Highlight: CMS modifies proposal to sunset the traditional MIPS reporting option, by finalizing a policy to sunset traditional MIPS after the CY 2030 performance period, rather than after the CY 2028 performance period.
Authorized by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), the Quality Payment Program (QPP) is a value-based payment program where Medicare-participating clinicians participate in either the Merit-based Incentive Payment System (MIPS) or an Advanced Alternative Payment Model (APM). CMS plans to continue developing policies for the QPP that increase opportunities for Advanced APM participation and to implement MIPS Value Pathways (MVPs) by connecting activities and measures from the four MIPS performance categories that are relevant to a specialty, medical condition, or a particular population.
- For the MIPS participation track, MIPS eligible clinicians are subject to a MIPS payment adjustment (positive, neutral, or negative) based on their performance in four performance categories: cost, quality, improvement activities, and promoting interoperability. For CY 2027 performance period/2029 MIPS payment year, the scoring weights are as follows: 30 percent for the quality performance category; 30 percent for the cost performance category; 15 percent for the improvement activities performance category; and 25 percent for the promoting interoperability performance category.
- For the Advanced APM track, if an eligible clinician participates in an Advanced APM and achieves Qualifying APM Participant (QP) or Partial QP status, they are excluded from the MIPS reporting requirements and payment adjustment. In alignment with the application of QPP eligibility determinations, CMS proposes to apply QP and Partial QP status to the TIN/NPI under which a clinician achieves QP or Partial QP status. Under current law, eligible clinicians who are QPs for the 2024 performance year/2026 payment year and beyond are subject to the qualifying APM conversion factor with an update of 0.75 percent.
Transforming MIPS: MIPS Value Pathway (MVP) Strategy – p. 1,565
CMS modified their proposal to sunset the traditional MIPS reporting option by finalizing a policy to sunset traditional MIPS after the CY 2030 performance period, rather than after the CY 2028 performance period. Beginning with the CY 2031 performance period/2033 MIPS payment year, MVPs will be the only MIPS reporting option for clinicians who don’t participate in a MIPS APM. Clinicians participating in a MIPS APM will continue to have the option to report the APM Performance Pathway (APP)/APP Plus.
Currently, there are three MIPS reporting options: MVPs, traditional MIPS, and APP, but CMS plans to move towards two reporting options in the QPP: MVPs and the APP. After consideration of public comments (p.1574-1590), CMS decided to delay the phaseout of traditional MIPS reporting by two years to allow more time to expand and refine MVPs, advance digital quality reporting, and help clinicians transition to the new requirements. Mandatory MVP or APP reporting will begin in performance year 2031, giving clinicians an additional year to adjust after mandatory digital quality reporting is expected to begin in 2030.
Even though CMS delayed the full transition to MVPs, CMS disagreed with commenters who urged to keep MVP reporting voluntary, arguing that maintaining traditional MIPS could slow MVP adoption and delay improvements in reporting simplicity and performance comparisons. However, CMS acknowledged concerns about the clinical relevance of existing MVPs and committed to working with stakeholders to improve specialty-specific measures and address reporting gaps.
CMS also finalized that virtual groups would be able to report an MVP beginning with the CY 2029 performance period (p.1,590).
CY 2027 MVP Development and Maintenance – p.1,594
CMS finalized proposals to add three new MVPs for a total of 30 MVPs in the CY 2027 performance period: Diabetic Disease; Hospitalist; and Hypertension. The Diabetic Disease and Hypertension MVPs are specifically designed to address the prevention of chronic illnesses by including measures and activities aimed at reducing the incidence and impact of long-term conditions. CMS also finalized, as proposed, modifications to the 27 previously finalized MVPs, including renaming the Rehabilitative Support for Musculoskeletal Care MVP to Rehabilitative Support MVP, and the identification of MIPS core measures in each MVP. (Note: see Appendix 3: MVP Inventory of the final rule on p.2,364-p.2,468 for the new and modified MVPs)
APM Performance Pathway (APP) – p.1,598
The APP was designed as a reporting and scoring pathway available only to MIPS-eligible clinicians identified as participating in a MIPS APM. The APP is intended to provide a predictable and consistent MIPS reporting option to reduce reporting burden and incentivize continued APM participation. CMS updated quality measures in the APP and APP Plus quality measure set by adopting measure specification changes to three measures (Diabetes: Glycemic Status Assessment Greater Than 9% (Quality ID: 001) (eCQMs collection type), Preventive Care and Screening: Screening for Depression and Follow-up Plan (Quality ID: 134) , and Hospital-Wide, 30-day, All-Cause Unplanned Readmission (HWR) Rate for MIPS Eligible Clinician Groups (Quality ID: 479)) and removing two measures (Initiation and Engagement of Substance Use Disorder Treatment (Quality ID: 305) and Adult Immunization Status (Quality ID: 493)). There will be 8 measures in the APP Plus quality measure set beginning with the CY 2027 performance period. (Note: see TABLE C-BC2: APP Plus Quality Measure Set for the CY 2027 performance period on p.1,607)
Fast Healthcare Interoperability Resources®-Based Digital Quality Measurement in the Quality Payment Program and Other CMS Quality Programs – Request for Information – p. 1,608
CMS aims to advance quality measurement by transitioning existing quality measures and reporting processes to FHIR®-based digital approaches. CMS previously proposed a phased transition, a 2-year transition period followed by required FHIR-based reporting for applicable measures, and sought input on a transition timeline, key milestones, and implementation considerations for FHIR-based quality reporting in the QPP and other CMS clinician and hospital quality programs. CMS did not finalize any policies regarding the FHIR-based approaches in this final rule but plans to address these issues in future rulemaking.
MIPS Performance Category Measures and Activities – p.1,611
- Quality Performance Category: CMS is finalizing a total of 180 quality measures for the CY 2027 performance period (QCDR measures are approved outside the rulemaking process and are excluded from this total.), including implementation of 10 new MIPS quality measures, removal of 20 MIPS quality measurers, and substantive changes to 43 current MIPS quality measures. (Note: for finalized MIPS quality measures, see Appendix 1: MIPS Quality Measures Table Group D on p.2,293-2,348)
MIPS Core Measures (p.1,614): CMS finalized the proposal to remove the high priority designation for quality measures (p.1,631) and is finalizing the 78 measures they proposed to be designated as MIPS core measures. MIPS eligible clinicians will be required to report a MIPS core measure, but small practices will be exempt.
- For traditional MIPS, clinicians will be required to report a MIPS core measure as one of their six quality measures. For MVPs, clinicians will be required to report a MIPS core measure as one of their four quality measures.
- If a clinician, group, virtual group, subgroup, or APM Entity reporting an MVP or traditional MIPS doesn’t have an applicable MIPS core measure available to report, CMS will implement a self-attestation process: 1) the clinician must attest that there wasn’t an applicable MIPS core measure available for them to report; and 2) the clinician must choose another measure to report in place of the MIPS core measure.
- Cost Performance Category: CMS finalized to update the operational list of care episode and patient condition groups and codes to reflect non-substantive measure maintenance updates. There are no proposed cost measure inventory updates for the CY 2027 performance period.
- Improvement Activities Performance Category: In alignment with the goal of promoting preventive care and fostering a more proactive and holistic approach to health management, CMS finalized addition of six new activities, modification of five existing activities, and removal of 11 activities for the CY 2027 performance period. (Note: See Table F-B1 in Appendix 2 (p.2,349) for more information regarding each of these proposed new improvement activities).
- MIPS Promoting Interoperability Performance Category: CMS finalized its proposal to remove the Office of the National Coordinator for Health Information Technology (ONC) attestations for the CY 2026 performance period and remove the required Security Risk Analysis measure starting with the CY 2027 performance period.
CMS also finalized changes to the Electronic Prior Authorization measure, making it optional in CY 2027 before requiring it in the CY 2028 performance period (p.1,748), while creating a new Electronic Prior Authorization for Prescription Drugs measure that will require the use of CEHRT to complete at least one prior authorization request for prescription drugs and medications (p.1,729). This new measure will become mandatory beginning in CY 2028.
MIPS Final Score Methodology – p.1,819
CMS finalized proposals to establish a policy for scoring MIPS core measures. If a MIPS eligible clinician submits data for more than one MIPS core measure, CMS will use the highest scoring MIPS core measure as one of the six or four quality measures, and the remaining scored measures will consist of either the five highest scoring quality measures or the three highest scoring measures, as applicable, in traditional MIPS and MVP reporting. If a MIPS eligible clinician, group, virtual group, subgroup, or APM entity reporting an MVP or traditional MIPS doesn’t report a MIPS core measure and isn’t a small practice, they will receive 0 out of 10 points for one of their required measures unless they submit an attestation that they don’t have an applicable core measure and submit another measure in its place.
Beginning in the CY 2027 performance period, CMS will score the quality performance category for Medicare Shared Savings Program ACOs by using flat benchmarks for Medicare CQMs and Medicare eCQMs. CMS also will retroactively apply flat benchmarks to three Medicare CQMs for the CY 2026 performance period, which includes Diabetes: Glycemic Status Assessment Greater Than 9%; Preventive Care and Screening: Screening for Depression and Follow-up Plan; and Controlling High Blood Pressure.
CMS also finalized its proposal to apply the defined topped out benchmark for topped out measures (i.e., measures for which measure performance is considered so high and unvarying that meaningful distinctions in performance can no longer be made). Fifteen quality measures will receive the previously defined topped out measure benchmarks for the CY 2027 performance period (Note: see TABLE C-H1 on p.1,831).
In the proposed rule, CMS solicited feedback through an RFI on the future direction of MVP scoring policies, including on a scoring methodology that would allow CMS to compare performance of clinicians more fairly within the same MVP, with each MVP focusing on measures and activities that are relevant to a given specialty or medical condition. CMS thanked the many comments the agency received in response to this RFI and will consider the feedback in future rulemaking (p.1,854).
Third Party Intermediaries General Requirements – p. 1,856
CMS finalized proposals to update their requirements for third party intermediaries related to conditions for approval for Qualified Clinical Data Registries (QCDRs) and qualified registries, data submissions, remove the additional requirements for health IT vendors, and update their remedial action/termination policies. Notably, CMS is:
- Requiring a QCDR or qualified registry to submit data for at least 6 quality measures, including at least one MIPS core measure, beginning in the CY 2027 performance period.
- Replacing “clinicians and groups” with “individual clinicians, groups, virtual groups, subgroups, and APM entities” to clarify that performance feedback must be provided at the level at which data were submitted.
- Clarifying that QCDRs or qualified registries submitting MIPS data for fewer than 10 QPP participants must include all participants in their data validation audits.
- Clarifying that when fewer than 5 patient records are available, the audit sample must include all patient records.
- Requiring third-party intermediaries that did not submit data in the preceding year to submit a participation plan with their self-nomination.
- Prohibiting changes to qualified posting information after its publication on the QPP website. All updates must be finalized during the qualified posting review period
- Terminating third-party intermediaries with participation plans that fail to provide CMS, by the specified deadline, documentation of contracts with QPP participants intending to submit MIPS data for the applicable performance period.
Calculating Final MIPS Score – p. 1,882
- Automatic Extreme and Uncontrollable Circumstances (EUC) Reweighting: CMS finalized removing the specification of a data source (PECOS) for clinician location, so that the agency has more flexibility to use the most up to date and accurate data source available to determine eligibility for reweighting under the automatic EUC policy, beginning with the CY 2027 performance period.
- Reweighting in Cases Where Data Aren’t Submitted by a Third-Party Intermediary: Beginning with the CY 2025 performance period/2027 MIPS payment year, CMS will extend the reweighting request deadline from November 1 to December 31 for clinicians whose MIPS data cannot be accessed or submitted due to circumstances beyond their control after delegating submission to a third-party intermediary
Public Reporting – p. 1,891
CMS will begin publicly reporting all eligible MIPS performance data for new Improvement Activities and Promoting Interoperability measures on the Medicare Compare Tool during their first year in the program. Currently, first-year data reported through the MVP framework are not publicly displayed. The change is intended to provide patients with more timely and comprehensive information about clinician performance.
Advanced APMs – p. 1,897
CMS will apply QP and Partial QP determinations at the TIN/NPI level to ensure that financial incentives are directed only to TINs actively participating in Advanced APMs. However, CMS is modifying their final policy in the following manner:
- Partial QP status will be extended to all TIN/NPI combinations for NPIs that achieve QP and Partial QP status based on individual determinations; and
- This modification will ensure participants in Advanced APMs who meet these thresholds are able to elect to participate in MIPS or be excluded.
As a result of the Consolidated Appropriations Act, 2026, CMS is updating the QP thresholds and partial QP thresholds for 2027 and beyond.
Optimal Care for Patients with Urologic Conditions MVP – p.2,427
The Optimal Care for Patients with Urologic Conditions MVP is designed to evaluate care for patients with a wide range of urologic conditions, including kidney stones, urinary incontinence, bladder cancer, and prostate cancer. CMS finalized the addition of three MIPS core measures for inclusion in the Urologic Conditions MVP and finalized the removal of AQUA8, AQUA14, AQUA15, and AQUA16 from the MVP.
Below is a summary table. Download the PDF here.
|
Measure ID |
Measure title |
CMS proposed action |
AUA feedback |
CMS final action (CMS comments) |
|
AQUA8 |
Hospital Admissions or Infectious Complications within 30 Days of Prostate Biopsy |
Remove from the MVP (high performing) |
Opposed removal |
Finalized as proposed (AQUA8 has had minimal variation in its historical benchmark) |
|
AQUA15 |
Stones: Urinalysis or Urine Culture Performed Before Surgical Stone Procedures |
Remove from the MVP (process measure); modify if retained |
Opposed removal |
Finalized/removed as proposed (AQUA15 only assesses for documentation of a urinalysis or urine culture and does not require a quality action or plan of care to account for abnormal results; therefore, missing a workflow step necessary to driving positive health outcomes) |
|
AQUA16 |
Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 Disease |
Remove from the MVP (low adoption, no benchmark after 2 consecutive years in MIPS) |
Opposed removal |
Finalized/removed as proposed (AQUA16 has not met the case minimum and reporting volumes required for benchmarking after being in the program for 2 consecutive years.) |
|
MUSIC4 |
Prostate Cancer: Active Surveillance/Watchful Waiting for Newly Diagnosed Low Risk Prostate Cancer Patients |
Modify |
Opposed proposed revision |
Not revised (will not be finalized as the measure steward determined no updates to the measure were necessary for CY 2027) |
|
AQUA14 |
Stones: Repeat Shock Wave Lithotripsy Within 6 Months of Initial Treatment |
Remove from the MVP (high performing), modify if retained |
Supported removal |
Finalized/removed as proposed (high performing) |
|
Q050 |
Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older |
Add to the MVP as a core measure |
Opposed designation of core measures |
Finalized as proposed (CMS acknowledged limitations in the selection of core measures due to the current inventory of MIPS quality measures and sought to balance measures aligned with MVP goals with those available for clinician reporting. CMS will review core measures annually and revise them as appropriate.) |
|
Q358 |
Patient-Centered Surgical Risk Assessment and Communication |
Add to the MVP as a core measure |
Opposed designation of core measures |
Finalized as proposed (same reason cited above for Q050) |
|
Q462 |
Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
Add to the MVP as a core measure |
Opposed designation of core measures |
Finalized as proposed (same reason cited above for Q050) |
|
IA_BE_16 |
Promote Self-management in Usual Care |
Add to Improvement Activities |
Supported |
Finalized as proposed |
|
IA_CC_9 |
Implementation of practices/processes for developing regular individual care plans |
Add to Improvement Activities |
Supported |
Finalized as proposed |
|
IA_BE_15 |
Engagement of Patients, Family, and Caregivers in Developing a Plan of Care |
Remove from Improvement Activities |
Supported |
Finalized as proposed |